Clinical evaluation of adjuvants

Immunopotentiators in Modern Vaccines

Volumn , Issue , 2006, Pages 319-342

  Simon, Jakub ^a   Edelman, Robert ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882485724     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012088403-2/50019-8     Document Type: Chapter

References (198)

1. Agrawal S., Kandimalla E.R. Medicinal chemistry and therapeutic potential of CpG DNA. Trends Mol. Med. 2002, 8:114-121.
2. Alonso P.L., Sacarlal J., Aponte J.J., Leach A., Macete E., Milman J., Mandomando I., Spiessens B., Guinovart C., Espasa M., Bassat Q., Aide P., Ofori-Anyinam O., Navia M.M., Corachan S., Ceuppens M., Dubois M.C., Demoitie M.A., Dubovsky F., Menendez C., Tornieporth N., Ballou W.R., Thompson R., Cohen J. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet 2004, 364:1411-1420.
3. Alving C.R. Design and selection of vaccine adjuvants: animal models and human trials. Vaccine 2002, 20:S56-S64.
4. Araneo B.A., Woods M.L., Daynes R.A. Reversal of the immunosenescent phenotype by dehydroepiandrosterone: hormone treatment provides an adjuvant effect on the immunization of aged mice with recombinant hepatitis B surface antigen. J. Infect. Dis. 1993, 167:830-840.
5. Arellano M., Waller K. Granulocyte-macrophagecolony-stimulating factor and other cytokines: as adjuncts to cancer immunotherapy, stem cell transplantation, and vaccines. Curr. Hematol. Rep. 2004, 3:424-431.
6. Baker P.J., Fauntleroy M.B., Stashak P.W., Hiernaux J.R., Cantrell J.L., Rudbach J.A. Adjuvant effects of trehalose dimycolate on the antibody response to type III pneumococcal polysaccharide. Infect. Immun. 1989, 57:912-917.
7. Baker P.J., Haslov K.R., Fauntleroy M.B., Stashak P.W., Myers K., Ulrich J.T. Enrichment of suppressor T cells by means of binding to monophosphoryl lipid A. Infect. Immun. 1990, 58:726-731.
8. Baldo V., Menegon T., Bonello C., Floreani A., Trivello R. Comparison of three different influenza vaccines in institutionalised elderly. Vaccine 2001, 19:3472-3475.
9. Baldridge J.R., Crane R.T. Monophosphoryl lipid A (MPL) formulations for the next generation of vaccines. Methods 1999, 19:103-107.
10. Baldridge J.R., Cluff C.W., Evans J.T., Lacy M.J., Stephens J.R., Brookshire V.G., Wang R., Ward J.R., Yorgensen Y.M., Persing D.H., Johnson D.A. Immunostimulatory activity of aminoalkyl glucosaminide 4-phosphates (AGPs): induction of protective innate immune responses by RC-524 and RC-529. J. Endotoxin Res. 2002, 8:453-458.
11. Barackman J.D., Ott G., Pine S., O'Hagan D.T. Oral administration of influenza vaccine in combination with the adjuvants LT-K63 and LT-R72 induces potent immune responses comparable to or stronger than traditional intramuscular immunization. Clin. Diagn. Lab. Immunol. 2001, 8:652-657.
12. Baylor N.W., Egan W., Richman P. Aluminum salts in vaccines: US perspective [correction appears in Vaccine (2002) 20, 3428]. Vaccine 2002, 20(Suppl. 3):S18-S23.
13. Beebe G.W., Simon A.H., Vivona S. Follow-up study on army personnel who received adjuvant influenza virus vaccine 1951-1953. Am. J. Med. Sci. 1964, 247:385-406.
14. Beebe G.W., Simon A.H., Vivona S. Long-term mortality follow-up of Army recruits who received adjuvant influenza virus vaccine in 1951-1953. Am. J. Epidemiol. 1972, 95:337-346.
15. Blennow M., Granstrom M., Olin P., Tiru M., Jaatmaa E., Askelof P., Sato Y. Preliminary data from a clinical trial (phase 2) of an acellular pertussis vaccine, J-NIH-6. Dev. Biol. Stand. 1986, 65:185-190.
16. Bojang K.A., Milligan P.J., Pinder M., Vigneron L., Alloueche A., Kester K.E., Ballou W.R., Conway D.J., Reece W.H., Gothard P., Yamuah L., Delchambre M., Voss G., Greenwood B.M., Hill A., McAdam K.P., Tornieporth N., Cohen J.D., Doherty T. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet 2001, 358:1927-1934.
17. Bollinger J.N. Metabolic fate of mineral oil adjuvants using 14C-labeled tracers: I. Mineral oil. J. Pharm. Sci. 1970, 59:1084-1088.
18. Brandenburg K., Lindner B., Schromm A., Koch M.H., Bauer J., merkli A., Zbaeren C., Davies J.G., Seydel U. Physicochemical characteristics of triacyl lipid A partial structure OM-174 in relation to biological activity. Eur. J. Biochem. 2000, 267:3370-3377.
19. Brunel F., Darbouret A., Ronco J. Cationic lipid DC-Chol induces an improved and balanced immunity able to overcome the unresponsiveness to the hepatitis B vaccine. Vaccine 1999, 17:2192-2203.
20. Bumford R. Aluminum salts: prospectives in their use as adjuvants. Immunological Adjuvants and Vaccines 1989, 35-41. Plenum Press, New York. G. Gregoriadis, A.C. Allison, G. Poste (Eds.).
21. Butler N.R., Feng S., Benson P.F., et al. Response of infants to pertussis vaccine at one week and to poliomyelitis, diptheria, and tetanus vaccine at six months. Lancet 1962, 2:112-114.
22. Byars N.E., Allison A.C., Harmon M.W., Kendal A.P. Enhancement of antibody responses to influenza B virus haemagglutinin by use of a new adjuvant formulation. Vaccine 1990, 8:49-56.
23. Campbell J.B., Peerbaye Y.A. Saponin. Res. Immunol. 1992, 143:526-530. discussion 577-578.
24. Cano C.A.D. The multi-epitope polypeptide approach in HIV-1 vaccine development. Genetic Anal. Biomolec. Eng. 1999, 15:149-153.
25. Carozzi S., Salit M., Cantaluppi A., Nasini M.G., Barocci S., Cantarella S., Lamperi S. Effect of monophosphoryl lipid A on the in vitro function of peritoneal leukocytes from uremic patients on continuous ambulatory peritoneal dialysis. J. Clin. Microbiol. 1989, 27:1748-1753.
26. Celis E. Getting peptide vaccines to work: just a matter of quality control. J. Clin. Invest. 2002, 110:1765-1768.
27. Chang D.Z., Lomazow W., Joy S.C., Stan R., Perales M.A. Granulocyte-macrophage colony stimulating factor: an adjuvant for cancer vaccines. Hematology 2004, 9:207-215.
28. Chedid L.A., Parant M.A., Audibert F.M., Riveau G.J., Parant F.J., Lederer E., Choay J.P., Lefrancier P.L. Biological activity of a new synthetic muramyl peptide adjuvant devoid of pyrogenicity. Infect. Immun. 1982, 35:417-424.
29. Claesson B.A., Trollfors B., Lagergard T., Taranger J., Bryla D., Otterman G., Cramton T., Yang Y., Reimer C.B., Robbins J.B. Clinical and immunologic responses to the capsular polysaccharide of Haemophilus influenzae type b alone or conjugated to tetanus toxoid in 18- to 23-month-old children. J. Pediatr. 1988, 112:695-702.
30. Clemens J.D., Sack D.A., Harris J.R., Chakraborty J., Khan M.R., Stanton B.F., Kay B.A., Khan M.U., Yunus M., Atkinson W. Field trial of oral cholera vaccines in Bangladesh. Lancet 1986, 2:124-127.
31. Coler R.N., Skeiky Y.A., Bernards K., Greeson K., Carter D., Cornellison C.D., Modabber F., Campos-Neto A., Reed S.G. Immunization with a polyprotein vaccine consisting of the T-cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and leishmania elongation initiation factor protects against leishmaniasis. Infect. Immun. 2002, 70:4215-4225.
32. Corey L., Langenberg A.G., Ashley R., Sekulovich R.E., Izu A.E., Douglas J.M., Handsfield H.H., Warren T., Marr L., Tyring S., DiCarlo R., Adimora A.A., Leone P., Dekker C.L., Burke R.L., Leong W.P., Straus S.E. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group. JAMA 1999, 282:331-340.
33. Couch R.B. Nasal vaccination, Escherichia coli enterotoxin, and Bell's palsy. N. Engl. J. Med. 2004, 350:860-861.
34. Coughlin R.T., Fattom A., Chu C., White A.C., Winston S. Adjuvant activity of QS-21 for experimental E. coli 018 polysaccharide vaccines. Vaccine 1995, 13:17-21.
35. Coughlin R.T., Fish D., Mather T.N., Ma J., Pavia C., Bulger P. Protection of dogs from Lyme disease with a vaccine containing outer surface protein (Osp) A, OspB, and the saponin adjuvant QS21. J. Infect. Dis. 1995, 171:1049-1052.
36. Cvjetanovic B., Uemura K. The present status of field and laboratory studies of typhoid and paratyphoid vaccines with special reference to studies sponsored by the World Health Organization. Bull WHO 1965, 32:29-36.
37. Danenberg H.D., Ben-Yehuda A., Zakay-Rones Z., Friedman G. Dehydroepiandrosterone (DHEA) treatment reverses the impaired immune response of old mice to influenza vaccination and protects from influenza infection. Vaccine 1995, 13:1445-1448.
38. Danenberg H.D., Ben Yehuda A., Zakay-Rones Z., Gross D.J., Friedman G. Dehydroepiandro-sterone treatment is not beneficial to the immune response to influenza in elderly subjects. J. Clin. Endocrinol. Metab. 1997, 82:2911-2914.
39. Davenport F.M. Seventeen years' experience with mineral oil adjuvant influenza virus vaccines. Ann. Allergy 1968, 26:288-292.
40. 4 on purified influenza virus haemagglutinins in man. J. Immunol. 1968, 100:1139-1140.
41. Davis H.L., Suparto I.I., Weeratna R.R., Jumintarto, Iskandriati D.D., Chamzah S.S., Ma'ruf A.A., Nente C.C., Pawitri D.D., Krieg A.M., Heriyanto, Smits W., Sajuthi D.D. CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans. Vaccine 2000, 18:1920-1924.
42. De Donato S., Granoff D., Minutello M., Lecchi G., Faccini M., Agnello M., Senatore F., Verweij P., Fritzell B., Podda A. Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly. Vaccine 1999, 17:3094-3101.
43. Descotes J., Ravel G., Ruat C. Vaccines: predicting the risk of allergy and autoimmunity. Toxicology 2002, 174:45-51.
44. Desombere I., Van der Wielen M., Van Damme P., Stoffel M., De Clercq N., Goilav C., Leroux-Roels G. Immune response of HLA DQ2 positive subjects, vaccinated with HBsAg/AS04, a hepatitis B vaccine with a novel adjuvant. Vaccine 2002, 20:2597-2602.
45. Dijkstra J., Mellors J.W., Ryan J.L., Szoka F.C. Modulation of the biological activity of bacterial endotoxin by incorporation into liposomes. J. Immunol. 1987, 138:2663-2670.
46. Diwan M., Khar R.K., Talwar G.P. Tetanus toxoid loaded "preformed microspheres" of cross-linked dextran. Vaccine 2001, 19:3853-3859.
47. Domer J.E., Human L.G., Andersen G.B., Rudbach J.A., Asherson G.L. Abrogation of suppression of delayed hypersensitivity induced by Candida albicans-derived mannan by treatment with monophosphoryl lipid A. Infect. Immun. 1993, 61:2122-2130.
48. R.Edelman Vaccine adjuvants. Rev. Infect. Dis. 1980, 2:370-383.
49. Edelman R., Tacket C.O. Adjuvants. Int. Rev. Immunol. 1990, 7:51-66.
50. Edelman R., Wasserman S.S., Kublin J.G., Bodison S.A., Nardin E.H., Oliveira G.A., Ansari S., Diggs C.L., Kashala O.L., Schmeckpeper B.J., Hamilton R.G. Immediate-type hypersensitivity and other clinical reactions in volunteers immunized with a synthetic multiantigen peptide vaccine (PfCS-MAP1NYU) against Plasmodium falciparum sporozoites. Vaccine 2002, 21:269-280.
51. Engers H., Kieny M.P., Malhotra P., Pink J.R. Third meeting on novel adjuvants currently in or close to clinical testing. Vaccine 2003, 21:3503-3524.
52. Ennis F.A., Cruz J., Jameson J., Klein M., Burt D., Thipphawong J. Augmentation of human influenza A virus-specific, cytotoxic T lymphocyte memory by influenza vaccine and adjuvanted, carriers (ISCOMS). Virology 1999, 259:256-261.
53. Evans J.T., Cluff C.W., Johnson D.A., Lacy M.J., Persing D.H., Baldridge J.R. Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and RIbi.529. Expert Rev. Vaccines 2003, 2:219-229.
54. Evans T.G., McElrath M.J., Matthews T., Montefiori D., Weinhold K., Wolff M., Keefer M.C., Kallas E.G., Corey L., Gorse G.J., Belshe R., Graham B.S., Spearman P.W., Schwartz D., Mulligan M.J., Goepfert P., Fast P., Berman P., Powell M., Francis D. QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immunization in humans. Vaccine 2001, 19:2080-2091.
55. Fattom A., Li X., Cho Y.H., Burns A., Hawwari A., Shepherd S.E., Coughlin R., Winston S., Naso R. Effect of conjugation methodology, carrier protein, and adjuvants on the immune response to Staphylococcus aureus capsular polysaccharides. Vaccine 1995, 13:1288-1293.
56. Fries L.F., Gordon D.M., Richards R.L., Egan J.E., Hollingdale M.R., Gross M., Silverman C., Alving C.R. Liposomal malaria vaccine in humans: a safe and potent adjuvant strategy. Proc. Natl. Acad. sci. USA 1992, 89:358-362.
57. Gao X., Huang L. A novel cationic liposome reagent for efficient transfection of mammalian cells. Biochem. Biophys. Res. Commun. 1991, 179:280-285.
58. Garg M., Subbarao B. Immune responses of systemic and mucosal lymphoid organs to Pnu: imune vaccine as a function of age, and the efficacy of monophosphoryl lipid A as an adjuvant. Infect. Immun. 1992, 60:2329-2336.
59. Genton B., Al Yaman F., Anders R., Saul A., Brown G., Pye D., Irving D.O., Briggs W.R., Mai A., Ginny M., Adiguma T., Rare L., Giddy A., Reber-Liske R., Stuerchler D., Alpers M.P. Safety and immunogenicity of a three-component blood-stage malaria vaccine in adults living in an endemic area of Papua New Guinea. Vaccine 2000, 18:2504-2511.
60. Gerard C.M., Baudson N., Kraemer K., Bruck C., Garcon N., Paterson Y., Pan Z.K., Pardoll D. Therapeutic potential of protein and adjuvant vaccinations on tumour growth. Vaccine 2001, 19:2583-2589.
61. Gherardi R.K., Coquet M., Cherin P., Belec L., Moretto P., Dreyfus P.A., Pellissier J.F., Chariot P., Authier F.J. Macrophagic myofasciitis lesions assess long-term persistence of vaccine-derived aluminium hydroxide in muscle. Brain 2001, 124:1821-1831.
62. Glenn G.M., Taylor D.N., Li X., Frankel S., Montemarano A., Alving C.R. Transcutaneous immunization: a human vaccine delivery strategy using a patch. Nature Med 2000, 6:1403-1406.
63. Gluck U., Gebbers J.O., Gluck R. Phase 1 evaluation of intranasal virosomal influenza vaccine with and without Escherichia coli heat-labile toxin in adult volunteers. J. Virol. 1999, 73:7780-7786.
64. Goldenthal K.L., Cavagnaro J.A., Alving C.R., Vogel F.R. NCVDG working groups: safety evaluation of vaccine adjuvants: national cooperative vaccine development meeting working group. AIDS Res. Hum. Retroviruses 1993, 9:S47-S51.
65. Gordon D.M., McGovern T.W., Krzych U., et al. Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine. J. Infect. Dis. 1995, 171:1576-1585.
66. Gordon D.M., Duffy P.E., Heppner D.G., Lyon J.A., Williams J.S., Scheumann D., Farley L., Stacey D., Haynes J.D., Sadoff J.C., Ballou W.R. Phase I safety and immunogenicity testing of clinical lots of the synthetic Plasmodium falciparum vaccine SPf66 produced under good manufacturing procedure conditions in the United States. Am. J. Trop. Med. Hyg. 1996, 55:63-68.
67. Guerena-Burgueno F., Hall E.R., Taylor D.N., Cassels F.J., Scott D.A., Wolf M.K., Roberts Z.J., Nesterova G.V., Alving C.R., Glenn G.M. Safety and immunogenicity of a prototype enterotoxigenic Escherichia coli vaccine administered transcutaneously. Infect. Immun. 2002, 70:1874-1880.
68. Gupta R.K. Aluminum compounds as vaccine adjuvants. Adv. Drug Deliv. Rev. 1998, 32:155-172.
69. Gupta R.K., Siber G.R. Adjuvants for human vaccines: current status, problems and future prospects. Vaccine 1995, 13:1263-1276.
70. Gupta R.K., Relyveld E.H., Lindblad E.B., Bizzini B., Ben-Efraim S., Gupta C.K. Adjuvants: a balance between toxicity and adjuvanticity. Vaccine 1993, 11:293-306.
71. Gupta R.K., Rost B.E., Relyveld E., Siber G.R. Adjuvant properties of aluminum and calcium compounds. Vaccine Design: The Subunit and Adjuvant Approach 1995, 229-248. Plenum Press, New York. M.F. Powell, M.J. Newman (Eds.).
72. Gustafson G.L., Rhodes M.J. Bacterial cell wall products as adjuvants: early interferon gamma as a marker for adjuvants that enhance protective immunity. Res. Immunol. 1992, 143:483-488. discussion 573-574.
73. Haigwood N.L., Nara P.L., Brooks E., Van Nest G.A., Ott G., Higgins K.W., Dunlop N., Scandella C.J., Eichberg J.W., Steimer K.S. Native but not denatured recombinant human immunodeficiency virus type 1 gp120 generates broad-spectrum neutralizing antibodies in baboons. J. Virol. 1992, 66:172-182.
74. Halperin S.A., Van Nest G., Smith B., Abtahi S., Whiley H., Eiden J.J. A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant. Vaccine 2003, 21:2461-2467.
75. Hardegree M.C., Pittman M., Maloney C.J. Influence of mouse strain on the assayed potency (unitage) of tetanus toxoid. Appl. Microbiol. 1972, 24:120-126.
76. Harper D.M., Franco E.L., Wheeler C., Ferris D.G., Jenkins D., Schuind A., Zahaf T., Innis B., Naud P., De Carvalho N.S., Roteli-Martins C.M., Teixeira J., Blatter M.M., Korn A.P., Quint W., Dubin G. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004, 364:1757-1765.
77. Heath A.W., Playfair J.H.L. Cytokines as immunological adjuvants. Vaccine 1992, 10:427-434.
78. Heineman T.C., Clements-Mann M.L., Poland G.A., Jacobson R.M., Izu A.E., Sakamoto D., Eiden J., Van Nest G.A., Hsu H.H. A randomized, controlled study in adults of the immunogenicity of a novel hepatitis B vaccine containing MF59 adjuvant. Vaccine 1999, 17:2769-2778.
79. Hoffman S.L., Edelman R., Bryan J.P., Schneider I., Davis J., Sedegah M., Gordon D., Church P., Gross M., Silverman C. Safety, immunogenicity, and efficacy of a malaria sporozoite vaccine administered with monophosphoryl lipid A, cell wall skeleton of mycobacteria, and squalane as adjuvant. Am. J. Trop. Med. Hyg. 1994, 51:603-612.
80. HogenEsch H. Mechanisms of stimulation of the immune response by aluminum adjuvants. Vaccine 2002, 20(Suppl. 3):S34-S39.
81. Holzer B.R., Hatz C., Schmidt-Sissolak D., Gluck R., Althaus B., Egger M. Immunogenicity and adverse effects of inactivated virosome versus alumadsorbed hepatitis A vaccine: a randomized controlled trial. Vaccine 1996, 14:982-986.
82. Hughes H.P., Babiuk L.A. The adjuvant potential of cytokines. Biotechnol. Ther. 1992, 3:101-117.
83. Hunter R.L. Overview of vaccine adjuvants: present and future. Vaccine 2002, 20(Suppl. 3):S7-S12.
84. Hunter R.L., Lal A.A. Copolymer adjuvants in malaria vaccine development. Am. J. Trop. Med. Hyg. 1994, 50(Suppl.):52-58.
85. Jacobson R.M., Adegbenro A., Pankratz V.S., Poland G.A. Adverse events and vaccination: the lack of power and predictability of infrequent events in pre-licensure study. Vaccine 2001, 19:2428-2433.
86. 3 as an immunological adjuvant. Acta Pathol. Microbiol. Immun. Scand. 1988, 96:257-264.
87. Johnson A.G., Gaines S., Landy M. Studies on the O antigen of Salmonella typhosa: V. Enhancement of antibody response to protein antigens by the purified lipopolysaccharide. J. Exp. Med. 1956, 103:225-246.
88. Jones W.R., Bradley J., Judd S.J., Denholm E.H., Ing R.M., Mueller U.W., Powell J., Griffin P.D., Stevens V.C. Phase I clinical trial of a World Health Organization birth control vaccine. Lancet 1988, 1:1295-1298.
89. Kasel J.A., Couch R.B., Douglas R.G. Antigenicity of alum and aqueous adenovirus hexon antigen vaccines in man. J. Immunol. 1971, 107:916-919.
90. Kashala O., Amador R., Valero M.V., Moreno A., Barbosa A., Nickel B., Daubenberger C.A., Guzman F., Pluschke G., Patarroyo M.E. Safety, tolerability and immunogenicity of new formulations of the Plasmodium falciparum malaria peptide vaccine SPf66 combined with the immunological adjuvant QS-21. Vaccine 2002, 20:2263-2277.
91. Keefer M.C., Wolff M., Gorse G.J., Graham B.S., Corey L., Clements-Mann M.L., Verani-Ketter N., Erb S., Smith C.M., Belshe R.B., Wagner N., McElrath M.J., Schwartz D.H., Fast P. Safety profile of phase I and II preventive HIV type 1 envelope vaccination: experience of the NIAID AIDS Vaccine Evaluation Group. AIDS Res. Hum. Retroviruses 1997, 13:1163-1177.
92. Keitel W., Couch R., Bond N., Adair S., Van Nest G., Dekker C. Pilot evaluation of influenza virus vaccine (IVV) combined with adjuvant. Vaccine 1993, 11:909-913.
93. Kenney R.T., Sacks D.L., Sypek J.P., Vilela L., Gam A.A., Evans-Davis K. Protective immunity using recombinant human IL-12 and alum as adjuvants in a primate model of cutaneous leishmaniasis. J. Immunol. 1999, 163:4481-4488.
94. Kenney R.T., Regina R.N., Pichyangkul S., Price V.L., Engers H.D. Second meeting on novel adjuvants currently in/close to human clinical testing. Vaccine 2002, 20:2155-2163.
95. Kensil C.R., Barrett C., Kushner N., Beltz G., Storey J., Patel U., Recchia J., Aubert A., Marciani D. Development of a genetically engineered vaccine against feline leukemia virus infection. J. Am. Vet. Med. Assoc. 1991, 199:1423-1427.
96. Kensil C.R., Patel U., Lennick M., Marciani D. Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex. J. Immunol. 1991, 146:431-437.
97. Kensil C.R., Wu J.Y., Soltysik S. Structural and immunological characterization of the vaccine adjuvant QS-21. Pharm. Biotechnol. 1995, 6:525-541.
98. Kleinau S., Erlandsson H., Holmdahl R., Klareskog L. Adjuvant oils induce arthritis in the DA rat: I. Characterization of the disease and evidence for an immunological involvement. J. Autoimmun. 1991, 4:871-880.
99. Kotloff K.L., Sztein M.B., Wasserman S.S., Losonsky G.A., DiLorenzo S.C., Walker R.I. Safety and immunogenicity of oral inactivated whole-cell Helicobacter pylori vaccine with adjuvant among volunteers with or without subclinical infection. Infect. Immun. 2001, 69:3581-3590.
100. Krieg A.M. From bugs to drugs: therapeutic immunomodulation with oligodeoxynucleotides containing CpG sequences from bacterial DNA. Antisense Nucleic Acid Drug Dev. 2001, 11:181-188.
101. Krieg A.M., Yi A.K., Matson S., Waldschmidt T.J., Bishop G.A., Teasdale R., Koretzky G.A., Klinman D.M. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995, 374:546-549.
102. Lachman L.B., Shih L.C., Rao X.M., Ullrich S.E., Cleland J.L. Cytokine-containing liposomes as adjuvants for subunit vaccines. Pharm. Biotechnol. 1995, 6:659-671.
103. Lambert J.S., McNamara J., Katz S.L., Fenton T., Kang M., VanCott T.C., Livingston R., Hawkins E., Moye J., Borkowsky W., Johnson D., Yogev R., Duliege A.M., Francis D., Gershon A., Wara D., Martin N., Levin M., McSherry G., Smith G. Safety and immunogenicity of HIV recombinant envelope vaccines in HIV-infected infants and children. National Institutes of Health-sponsored Pediatric AIDS Clinical Trials Group (ACTG-218). J. AIDS Hum. Retrovirol. 1998, 19:451-461.
104. Langenberg A.G., Burke R.L., Adair S.F., Sekulovich R., Tigges M., Dekker C.L., Corey L. A recombinant glycoprotein vaccine for herpes simplex virus type 2: safety and immunogenicity [corrected; published erratum appears in Ann. Intern. Med. (1995) 123, 395]. Ann. Intern. Med. 1995, 122:889-898.
105. Lawrence G., Cheng Q.Q., Reed C., Taylor D., Stowers A., Cloonan N., Rzepczyk C., Smillie A., Anderson K., Pombo D., Allworth A., Eisen D., Anders R., Saul A. Effect of vaccination with 3 recombinant asexualstage malaria antigens on initial growth rates of Plasmodium falciparum in non-immune volunteers. Vaccine 2000, 18:1925-1931.
106. Lawrence G.W., Saul A., Giddy A.J., Kemp R., Pye D. Phase I trial in humans of an oil-based adjuvant SEPPIC MONTANIDE ISA 720. Vaccine 1997, 15:176-178.
107. Leroux-Roels G., Moreux E., Verhasselt B., et al. Immunogenicity and reactogenicity of a recombinant HSV-2 glycoprotein D vaccine with or without monophosphoryl lipid A in HSV seronegative and seropositive subjects. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy 1993, 341.
108. Lin R., Tarr P.E., Jones T.C. Present status of the use of cytokines as adjuvants with vaccines to protect against infectious diseases. Clin. Infect. Dis. 1995, 21:1439-1449.
109. Livingston P.O., Adluri S., Helling F., Yao T.J., Kensil C.R., Newman M.J., Marciani D. Phase 1 trial of immunological adjuvant QS-21 with a GM2 gangliosidekeyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma. Vaccine 1994, 12:1275-1280.
110. Lopez J.A., Weilenman C., Audran R., Roggero M.A., Bonelo A., Tiercy J.M., Spertini F., Corradin G. A synthetic malaria vaccine elicits a potent CD8(+) and CD4(+) T lymphocyte immune response in humans. Implications for vaccination strategies. Eur. J. Immunol. 2001, 31:1989-1998.
111. Lovgren K. The serum antibody response distributed in subclasses and isotypes after intranasal and subcutaneous immunization with influenza virus immunostimulating complexes. Scand. J. Immunol. 1988, 27:241-245.
112. Luderitz O., Galanos S., Reitschel E.T. Endotoxins of gram-negative bacteria. Pharm. Ther. 1982, 15:383-402.
113. Ludewig B., Ochsenbein A.F., Odermatt B., Paulin D., Hengartner H., Zinkernagel R.M. Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease. J. Exp. Med. 2000, 191:795-804.
114. Lyng J., Nyerges G. The second international standard for tetanus toxoid (adsorbed). J. Biol. Stand. 1984, 12:121-130.
115. MacLean G.D., Bowen-Yacyshyn M.B., Samuel J., Meikle A., Stuart G., Nation J., Poppema S., Jerry M., Koganty R., Wong T. Active immunization of human ovarian cancer patients against a common carcinoma (Thomsen-Friedenreich) determinant using a synthetic carbohydrate antigen. J. Immunother. 1992, 11:292-305.
116. MacLean G.D., Reddish M., Koganty R.R., Wong T., Gandhi S., Smolenski M., Samuel J., Nabholtz J.M., Longenecker B.M. Immunization of breast cancer patients using a synthetic sialyl-Tn glycoconjugate plus Detox adjuvant. Cancer Immunol. Immunother. 1993, 36:215-222.
117. Marciani D.J., Kensil C.R., Beltz G.A., Hung C.H., Cronier J., Aubert A. Genetically engineered subunit vaccine against feline leukaemia virus: protective immune response in cats. Vaccine 1991, 9:89-96.
118. Mark A., Bjorksten B., Granstrom M. Immunoglobulin E responses to diphtheria and tetanus toxoids after booster with aluminium-adsorbed and fluid DT-vaccines. Vaccine 1995, 13:669-673.
119. Martin M., Michalek S.M., Katz J. Role of innate immune factors in the adjuvant activity of monophosphoryl lipid A. Infect. Immun. 2003, 71:2498-2507.
120. Matsuhasi T. Influence of mouse strain on the results of potency testing for diphtheria and tetanus toxoid components of D, T, DT and DTP vaccines. Publication No. (FDA) 91-1174 1991, 55-58. Department of Health and Human Services, US Public Health Service, Bethesda, MD. C.R. Manclark (Ed.).
121. McCormack S., Tilzey A., Carmichael A., Gotch F., Kepple J., Newberry A., Jones G., Lister S., Beddows S., Cheingsong R., Rees A., Babiker A., Banatvala J., Bruck C., Darbyshire J., Tyrrell D., Van Hoecke C., Weber J. A phase I trial in HIV negative healthy volunteers evaluating the effect of potent adjuvants on immunogenicity of a recombinant gp120W61D derived from dual tropic R5X4 HIV-1ACH320. Vaccine 2000, 18:1166-1177.
122. Meraldi V., Audran R., Romero J.F., Brossard V., Bauer J., Lopez J.A., Corradin G. OM-174, a new adjuvant with a potential for human use, induces a protective response when administered with the synthetic C-terminal fragment 242-310 from the circumsporozoite protein of Plasmodium berghei. Vaccine 2003, 21:2485-2491.
123. Mitchell M.S., Kan-Mitchell J., Kempf R.A., Harel W., Shau H.Y., Lind S. Active specific immunotherapy for melanoma: phase I trial of allogeneic lysates and a novel adjuvant. Cancer Res. 1988, 48:5883-5893.
124. Morein B., Sundquist B., Hoglund S., Dalsgaard K., Osterhaus A. Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses. Nature 1984, 308:457-460.
125. Moron G., Dadaglio G., Leclerc C. New tools for antigen delivery to the MHC class I pathway. Trends Immunol. 2004, 25:92-97.
126. Murphey-Corb M., Ohkawa S., Martin L., et al. Comparative efficacy of a whole killed SIV vaccine in combination with various adjuvants. Sixth Annual Meeting of the National Cooperative Vaccine Development Group for AIDS 1993.
127. Murray P.J., Aldovini A., Young R.A. Manipulation and potentiation of antimycobacterial immunity using recombinant bacille Calmette-Guerin strains that secrete cytokines. Proc. Natl. Acad. Sci. USA 1996, 93:934-939.
128. Murray R., Cohen P., Hardegree M.C. Mineral oil adjuvants: biological and chemical studies. Ann. Allergy 1972, 30:146-151.
129. Mutsch M., Zhou W., Rhodes P., Bopp M., Chen R.T., Linder T., Spyr C., Steffen R. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N. Engl. J. Med. 2004, 350:896-903.
130. Myers K.R., Truchot A.T., Ward J., et al. A critical determinant of lipid A endotoxic activity. Cellular and Molecular Aspects of Endotoxin Reactions 1996, 145-156. Elsevier, Amsterdam. A. Nowotny, J.J. Spitzer, E.J. Ziegler (Eds.).
131. Nardin E.H., Oliveira G.A., Calvo-Calle J.M., Castro Z.R., Nussenzweig R.S., Schmeckpeper B., Hall B.F., Diggs C., Bodison S., Edelman R. Synthetic malaria peptide vaccine elicits high levels of antibodies in vaccinees of defined HLA genotypes. J. Infect. Dis. 2000, 182:1486-1496.
132. Newman M.J., Wu J.Y., Coughlin R.T., Murphy C.I., Seals J.R., Wyand M.S., Kensil C.R. Immunogenicity and toxicity testing of an experimental HIV-1 vaccine in nonhuman primates. AIDS Res. Hum. Retroviruses 1992, 8:1413-1418.
133. Newman M.J., Wu J.Y., Gardner B.H., Munroe K.J., Leombruno D., Recchia J., Kensil C.R., Coughlin R.T. Saponin adjuvant induction of ovalbumin-specific CD8+ cytotoxic T lymphocyte responses. J. Immunol. 1992, 148:2357-2362.
134. Newman M.J., Munroe K.J., Anderson C.A., Murphy C.I., Panicali D.L., Seals J.R., Wu J.Y., Wyand M.S., Kensil C.R. Induction of antigen-specific killer T lymphocyte responses using subunit SIVmac251 gag and env vaccines containing QS-21 saponin adjuvant. AIDS Res. Hum. Retroviruses 1994, 10:853-861.
135. Newman M.J., Wu J.Y., Gardner B.H., Anderson C.A., Kensil C.R., Recchia J., Coughlin R.T., Powell M.F. Induction of cross-reactive cytotoxic T-lymphocyte responses specific for HIV-1 gp120 using saponin adjuvant (QS-21) supplemented subunit vaccine formulations. Vaccine 1997, 15:1001-1007.
136. O'Hagan D.T., Jeffery H., Davis S.S. Long-term antibody responses in mice following subcutaneous immunization with ovalbumin entrapped in biodegradable microparticles. Vaccine 1993, 11:965-969.
137. Ott G., Barchfeld G.L., et al. MF59: design and evaluation of a safe and potent adjuvant for human vaccines. Vaccine Design: The Subunit and Adjuvant Approach 1995, 277-296. Plenum Press, New York. M.F. Powell, M.J. Newman (Eds.).
138. Ozel M., Hoglund S., Gelderblom H.R., Morein B. Quaternary structure of the immunostimulating complex (iscom). J. Ultrastruct. Mol. Struct. Res. 1989, 102:240-248.
139. Page W.F., Norman J.E., Benenson A.S. Longterm follow-up of army recruits immunized with Freund's incomplete adjuvanted vaccine. Vaccine Res. 1993, 2:141-149.
140. Patou G., Scott G.M., Kelsey M.C., Playfair J.H.L. Gamma interferon as an adjuvant to hepatitis B vaccine. J. Interferon Res. 1989, 9:S261.
141. Pearson C.M. Experimental joint disease: observations on adjuvant-induced arthritis. J. Chronic Dis. 1963, 16:863-874.
142. Peppoloni S., Ruggiero P., Contorni M., Morandi M., Pizza M., Rappuoli R., Podda A., Del Giudice G. Mutants of the Escherichia coli heat-labile enterotoxin as safe and strong adjuvants for intranasal delivery of vaccines. Expert Rev. Vaccines. 2003, 2:285-293.
143. Pink J.R., Kieny M.P. Fourth meeting on novel adjuvants currently in/close to human clinical testing. Vaccine 2004, 22:2097-2102.
144. Powell M.F., Cleland J.L., Eastman D.J., Lim A., Murthy K., Newman M.J., Nunberg J.H., Weissburg R.P., Vennari J.C., Wrin T. Immunogenicity and HIV-1 virus neutralization of MN recombinant glycoprotein 120/HIV-1 QS21 vaccine in baboons [published erratum appears in AIDS Res. Hum. Retroviruses (1995) 11, 661]. AIDS Res. Hum. Retroviruses 1994, 10(Suppl. 2):S105-S108.
145. Qureshi N., Takayama K., Ribi E. Purification and structural determination of nontoxic lipid A obtained from the lipopolysaccharide of Salmonella typhimurium. J. Biol. Chem. 1982, 257:11808-11815.
146. Ragde H., Cavanagh W.A., Tjoa B.A. Dendritic cell based vaccines: progress in immunotherapy studies for prostate cancer. J. Urol. 2004, 172:2532-2538.
147. Ramon G. Procedes pour accroitre la production des antitoxines. Ann. Inst. Pasteur 1926, 40:1-10.
148. Ratliff D.A., Burns-Cox C.J. Anaphylasix to tetanus toxoid. Br. Med. J. 1984, 288:114.
149. Ribi E., Amano K., Cantrell J., Schwartzman S., et al. Preparation and antitumor activity of nontoxic lipid A. Cancer Immunol. Immunother. 1982, 12:91-96.
150. Ribi E., Cantrell J., Takayama K., et al. Modulation of humoral and cell-mediated immune responses by a structurally established nontoxic lipid A. Immunobiology and Immunopharmacology of Bacterial Endotoxins 1986, 407-420. Plenum Press, New York. A. Szentivanyi, H. Friedman (Eds.).
151. Rimmelzwaan G.F., Osterhaus A.D.M.E. A novel generation of viral vaccines based on the ISCOM matrix. The Subunit and Adjuvant Approach 1995, 543-558. Plenum Press, New York. M.F. Powell, M.J. Newman (Eds.).
152. Rinn K., Schiffman K., Otero H.O., Disis M.L. Antigen-specific recall urticaria to a peptide-based vaccine. J. Allergy Clin. Immunol. 1999, 104:240-242.
153. Ronnberg B., Fekadu M., Morein B. Adjuvant activity of non-toxic Quillaja saponaria Molina components for use in ISCOM matrix. Vaccine 1995, 13:1375-1382.
154. Ryan E.J., McNeela E., Murphy G.A., Stewart H., O'Hagan D., Pizza M., Rappuoli R., Mills K.H. Mutants of Escherichia coli heat-labile toxin act as effective mucosal adjuvants for nasal delivery of an acellular pertussis vaccine: differential effects of the nontoxic AB complex and enzyme activity on Th1 and Th2 cells. Infect. Immun. 1999, 67:6270-6280.
155. Ryan E.T., Calderwood S.B. Cholera vaccines. Clin. Infect. Dis. 2000, 31:561-565.
156. Salk J., Salk D. Control of influenza and poliomyelitis with killed virus vaccines. Science 1977, 195:834-847.
157. Sanchez-Pescador L., Burke R.L., Ott G., Van Nest G. The effect of adjuvants on the efficacy of a recombinant herpes simplex virus glycoprotein vaccine. J. Immunol. 1988, 141:1720-1727.
158. Saul A., Lawrence G., Smillie A., Rzepczyk C.M., Reed C., Taylor D., Anderson K., Stowers A., Kemp R., Allworth A., Anders R.F., Brown G.V., Pye D., Schoofs P., Irving D.O., Dyer S.L., Woodrow G.C., Briggs W.R., Reber R., Sturchler D. Human phase I vaccine trials of 3 recombinant asexual stage malaria antigens with Montanide ISA720 adjuvant. Vaccine 1999, 17:3145-3159.
159. Schirmbeck R., Kuhrober A., Janowicz Z.A., Reimann J. Immunization with soluble hepatitis B virus surface protein elicits murine H-2 class I-restricted CD8+ cytotoxic T lymphocyte responses in vivo. J. Immunol. 1994, 152:1110-1119.
160. Schneerson R., Fattom A., Szu S.C., Bryla D., Ulrich J.T., Rudbach J.A., Schiffman G., Robbins J.B. Evaluation of monophosphoryl lipid A (MPL) as an adjuvant. Enhancement of the serum antibody response in mice to polysaccharide-protein conjugates by concurrent injection with MPL. J. Immunol. 1991, 147:2136-2140.
161. Schultz N., Oratz R., Chen D., Zeleniuch-Jacquotte A., Abeles G., Bystryn J.C. Effect of DETOX as an adjuvant for melanoma vaccine. Vaccine 1995, 13:503-508.
162. Scott P. IL-12: initiation cytokine for cell-mediated immunity [comment]. Science 1993, 260:496-497.
163. Shirai M., Pendleton C.D., Ahlers J., Takeshita T., Newman M., Berzofsky J.A. Helper-cytotoxic T lymphocyte (CTL) determinant linkage required for priming of anti-HIV CD8+CTL in vivo with peptide vaccine constructs. J. Immunol. 1994, 152:549-556.
164. Siber G.R., Anderson R., Habafy M., Gupta R.K. Development of a guinea pig model to assess immunogenicity of Haemophilus influenzae type b capsular polysaccharide conjugate vaccines. Vaccine 1995, 13:525-531.
165. Siegrist C.A., Pihlgren M., Tougne C., Efler S.M., Morris M.L., AlAdhami M.J., Cameron D.W., Cooper C.L., Heathcote J., Davis H.L., Lambert P.H. Co-administration of CpG oligonucleotides enhances the late affinity maturation process of human anti-hepatitis B vaccine response. Vaccine 2004, 23:615-622.
166. Slingluff C.L., Yamshchikov G., Neese P., Galavotti H., Eastham S., Engelhard V.H., Kittlesen D., Deacon D., Hibbitts S., Grosh W.W., Petroni G., Cohen R., Wiernasz C., Patterson J.W., Conway B.P., Ross W.G. Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes. Clin. Cancer Res. 2001, 7:3012-3024.
167. Sommer F., Wilken H., Faller G., Lohoff M. Systemic Th1 immunization of mice against Helicobacter pylori infection with CpG oligodeoxynucleotides as adjuvants does not protect from infection bu. Infect. Immun. 2004, 72:1029-1035.
168. Stanberry L.R., Spruance S.L., Cunningham A.L., Bernstein D.I.aiMindel A., Sacks S., Tyring S., Aoki F.Y., Saloui M., Denis M., Vandepapeloiere P., Dubin G. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N. Engl. J. Med. 2002, 347:1652-1661.
169. Stevenson M.M., Su Z., Sam H., Mohan K. Modulation of host responses to blood-stage malaria by interleukin-12: from therapy to adjuvant activity. Microbes. Infect. 2001, 3:49-59.
170. Stewart-Tull D.E.S. Recommendations for the assessment of adjuvants (immunopotentiators). Immunological Adjuvants and Vaccines 1989, 213-226. Plenum Press, New York. G. Gregoriadis, A.C. Allison, G. Poste (Eds.).
171. Stieneker F., Kersten G., van Bloois L., Crommelin D.J., Hem S.L., Lower J., Kreuter J. Comparison of 24 different adjuvants for inactivated HIV-2 split whole virus as antigen in mice. Induction of titres of binding antibodies and toxicity of the formulations. Vaccine 1995, 13:45-53.
172. Storni T., Ruedl C., Schwarz K., Schwendener R.A., Renner W.A., Bachmann M.F. Nonmethylated CG motifs packaged into virus-like particles induce protective cytotoxic T cell responses in the absence of systemic side effects. J. Immunol. 2004, 172:1777-1785.
173. Stoute J.A., Slaoui M., Heppner D.G., Momin P., Kester K.E., Desmons P., Wellde B.T., Garcon N., Krzych U., Marchand M. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group [see comments]. N. Engl. J. Med. 1997, 336:86-91.
174. Stuart-Harris C.H. Adjuvant influenza vaccines. Bull. WHO 1969, 41:617-621.
175. Sturchler D., Berger R., Etlinger H., Fernex M., Matile H., Pink R., Schlumbom V., Just M. Effects of interferons on immune response to a synthetic peptide malaria sporozoite vaccine in non-immune adults. Vaccine 1989, 7:457-461.
176. Sundquist B., Lovgren K., Morein B. Influenza virus ISCOMs: antibody response in animals. Vaccine 1988, 6:49-53.
177. Takeshita F., Leifer C.A., Gursel I., Ishii K.J., Takeshita S., Gursel M., Klinman D.M. Cutting edge: role of Toll-like receptor 9 in CpG DNA-induced activation of human cells. J. Immunol. 2001, 167:3555-3558.
178. Tao M.H., Levy R. Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma [see comments]. Nature 1993, 362:755-758.
179. Telzak E., Wolff S.M., Dinarello C.A., Conlon T., el Kholy A., Bahr G.M., Choay J.P., Morin A., Chedid L. Clinical evaluation of the immunoadjuvant murabutide, a derivative of MDP, administered with a tetanus toxoid vaccine. J. Infect. Dis. 1986, 153:628-633.
180. Thapar M.A., Parr E.L., Bozzola J.J., Parr M.B. Secretory immune responses in the mouse vagina after parenteral or intravaginal immunization with an immunostimulating complex (ISCOM). Vaccine 1991, 9:129-133.
181. Tiberio L., Fletcher L., Eldridge J.H., Duncan D.D. Host factors impacting the innate response in humans to the candidate adjuvants RC529 and monophosphoryl lipid A. Vaccine 2004, 22:1515-1523.
182. Toledo H., Baly A., Castro O., Resik S., Laferte J., Rolo F., Navea L., Lobaina L., Cruz O., Miguez J., Serrano T., Sierra B., Perez L., Ricardo M.E., Dubed M., Lubian A.L., Blanco M., Millan J.C., Ortega A., Iglesias E., Penton E., Martin Z., Perez J., Diaz M., Duarte C.A. A phase I clinical trial of a multi-epitope polypeptide TAB9 combined with Montanide ISA 720 adjuvant in non-HIV-1 infected human volunteers. Vaccine 2001, 19:4328-4336.
183. Ulrich J.T., Myers K.R. Monophosphoryl lipid A as an adjuvant: past experiences and new directions. The Subunit and Adjuvant Approach 1995, 495-524. Plenum Press, New York. M.F. Powell, M.J. Newman (Eds.).
184. Valensi J.P., Carlson J.R., Van Nest G.A. Systemic cytokine profiles in BALB/c mice immunized with trivalent influenza vaccine containing MF59 oil emulsion and other advanced adjuvants. J. Immunol. 1994, 153:4029-4039.
185. Van Dam G.J., Verheul A.F., Zigterman G.J., De Reuver M.J., Snippe H. Nonionic block polymer surfactants enhance the avidity of antibodies in polyclonal antisera against Streptococcus pneumoniae type 3 in normal and Xid mice. J. Immunol. 1989, 143:3049-3053.
186. Van Driel W.J., Ressing M.E., Kenter G.G., Brandt R.M., Krul E.J., van Rossum A.B., Schuuring E., Offringa R., Bauknecht T., Tamm-Hermelink A., van Dam P.A., Fleuren G.J., Kast W.M., Melief C.J., Trimbos J.B. Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial. Eur. J. Cancer 1999, 35:946-952.
187. Van Loon F.P., Clemens J.D., Chakraborty J., Rao M.R., Kay B.A., Sack D.A., Yunus M., Ali M., Svennerholm A.M., Holmgren J. Field trial of inactivated oral cholera vaccines in Bangladesh: results from 5 years of follow-up. Vaccine 1996, 14:162-166.
188. Verdier F. Non-clinical vaccine safety assessment. Toxicology 2002, 174:no37-no43.
189. Vernacchio L., Bernstein H., Pelton S., Allen C., MacDonald K., Dunn J., Duncan D.D., Tsao G., LaPosta V., Eldridge J., Laussucq S., Ambrosino D.M., Molrine D.C. Effect of monophosphoryl lipid A (MPL) on T-helper cells when administered as an adjuvant with pneumocococcal-CRM197 conjugate vaccine in healthy toddlers. Vaccine 2002, 20:3658-3667.
190. Verthelyi D., Kenney R.T., Seder R.A., Gam A.A., Friedag B., Klinman D.M. CpG oligodeoxynucleotides as vaccine adjuvants in primates. J. Immunol. 2002, 168:1659-1663.
191. Villacres M.C., Behboudi S., Nikkila T., Lovgren-Bengtsson K., Morein B. Internalization of iscom-borne antigens and presentation under MHC class I or class II restriction. Cell Immunol. 1998, 185:30-38.
192. Villaret D., Glisson B., Kenady D., Hanna E., Carey M., Gleich L., Yoo G.H., Futran N., Hung M.C., Anklesaria P., Heald A.E. A multicenter phase II study of tgDCC-E1A for the intratumoral treatment of patients with recurrent head and neck squamous cell carcinoma. Head Neck 2002, 24:661-669.
193. Wheeler A.W., Woroniecki S.R. Allergy vaccines: new approaches to an old concept. Expert Opin. Biol. Ther. 2004, 4:1473-1481.
194. Woolridge R.L., Grayston J.T., Chang I.A., et al. Long-term follow-up of the initial (1959-1960) trachoma vaccine field on Taiwan. Am. J. Ophthalmol. 1967, 63:1650-1653.
195. World Health Organization Manual for the Production and Control of Vaccines: Tetanus Toxoid 1977, World Health Organization.
196. Wu J.Y., Gardner B.H., Murphy C.I., Seals J.R., Kensil C.R., Recchia J., Beltz G.A., Newman G.W., Newman M.J. Saponin adjuvant enhancement of antigen-specific immune responses to an experimental HIV-1 vaccine. J. Immunol. 1992, 148:1519-1525.
197. Zhou F., Huang L. Monophosphoryl lipid A enhances specific CTL induction by a soluble protein antigen entrapped in liposomes. Vaccine 1993, 11:1139-1144.
198. Zigterman G.J., Schotanus K., Ernste E.B., Van Dam G.J., Jansze M., Snippe H., Willers J.M. Nonionic block polymer surfactants modulate the humoral immune response against Streptococcus pneumoniae-derived hexasaccharide- protein conjugates. Infect. Immun. 1989, 57:2712-2718.